Strand Life Sciences, a bioinformatics company, introduced liquid biopsy test portfolio called Strand LB that helps in highly sensitive detection of tumour traces from a simple blood draw.
While tumours are usually assessed through invasive biopsies or through radioactive scans, this test will ensure early and precise indication of tumour presence, cancer recurrence, and response to therapy, said the company in a statement.